Evidence map›Paper›PMID 26752138›Full record

Trial reportBone marrow transplantation2016

A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: a single-institutional experience.

J Shang, H Wang, J Sun, Z Fan, F Huang, Y Zhang, Q Jiang, M Dai, N Xu, R Lin and 1 more

Abstract readClinical TrialComparative Study
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 3 pooled it
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Prophylaxis for Hepatitis B Virus Reactivation after Allogeneic Stem Cell Transplantation in the Era of Drug Resistance and Newer Antivirals: A Systematic Review and Meta-Analysis.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018
    Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2018
    Article
  15. Article
  16. Review
  17. Review
  18. Hepatitis B Reactivation in the Treatment of Non-Hodgkin Lymphoma.Cancer control : journal of the Moffitt Cancer Center
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

J ShangDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
H WangDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
J SunDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Z FanDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
F HuangDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Y ZhangDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Q JiangDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
M DaiDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
N XuDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
R LinDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Q LiuDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Nanfang Hospital · CNSouthern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to compare the efficacy of lamivudine vs entecavir in the prevention of hepatitis B virus (HBV) reactivation in HBV surface Ag (HBsAg)-positive patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). A total of 216 consecutive patients were enrolled and retrospectively reviewed. Of these patients, 119 received lamivudine and 97 received entecavir. The median treatment duration to complete virological response in patients with baseline HBV-DNA levels >10(5) copies/mL was 2.0 months in the entecavir group, significantly shorter than that of the lamivudine group. After a median follow-up of 24 months post transplantation, the cumulative incidence rates of HBV reactivation at 6, 12 and 24 months following transplantation were 3.0%, 7.0% and 24.0% in the lamivudine group, and 0%, 0% and 2.0% in the entecavir group, respectively. In addition, entecavir treatment was associated with lower cumulative incidence rates of severe hepatitis caused by HBV reactivation. Mutations leading to drug resistance were detected in 25 patients in the lamivudine group and in only one patient in the entecavir group. Our data indicate that compared with lamivudine, entecavir has more potent antiviral efficacy and may be a better choice for prophylaxis of HBV reactivation in HBsAg-positive allo-HSCT recipients.

Indexed as

Hematopoietic Stem Cell TransplantationAdolescentAdultAllograftsFemaleFollow-Up StudiesGuanineHepatitis BHepatitis B virusHumansLamivudineMaleMiddle AgedVirus ActivationentecavirGuanineLamivudine

Identifiers

PMID26752138
OpenAlexW2238435065

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.